RecruitingNot ApplicableNCT06694636
Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
Sponsor
Zhongda Hospital
Enrollment
5 participants
Start Date
Feb 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Patients who met the inclusion criteria were treated with endovascular radiofrequency ablation and desympathetic nerve surgery. After enrollment, endovascular radiofrequency ablation and desympathetic surgery were performed. After radiofrequency ablation, the safety and efficacy of follow-up treatment will be carried out every 1 month or so, including blood routine, liver and kidney function, tumor indicators, abdominal CT/magnetic resonance, etc.
Eligibility
Min Age: 25 YearsMax Age: 75 Years
Inclusion Criteria4
- Clinically or pathologically confirmed hepatocellular carcinoma (HCC)
- Locally progressed or distant metastatic unresectable advanced HCC
- Progressed after second-line therapy
- Agree to participate in the study and sign the informed consent form
Exclusion Criteria10
- Not suitable for ablation surgery
- Pregnant, lactating and planning to become pregnant
- Orthostatic hypotension
- Mixed liver cancer
- Intestinal obstruction
- Obvious bleeding tendencies and hematologic diseases
- Acute or severe systemic infection;
- Stroke or transient ischemic attack (TIA) within two weeks;
- Acute coronary syndrome within two weeks;
- Evaluated to be not suitable for this trial by investigators
Interventions
PROCEDUREendovascular radiofrequency ablation and desympathetic nerve surgery
endovascular radiofrequency ablation and desympathetic nerve surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06694636
Related Trials
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
NCT056298451 location
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
NCT0679611410 locations
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
NCT054683592 locations
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT0552895214 locations